Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.
Suchita Pakkala, MD, assistant professor, Department of Hematology and Medical Oncology, site medical director, Infusion Services, Emory University School of Medicine, Emory University Hospital Midtown, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.
The role of local therapy in the metastatic setting is currently being evaluated in HER2-positive breast cancer, Pakkala begins. In the phase 2 HER2CLIMB (NCT02614794) trial, patients with metastatic HER2-positive breast cancer who were previously treated with local central nervous system (CNS) therapy and stable brain metastases or experienced subsequent disease progression were still to permitted to enroll on the study. HER2CLIMB evaluated the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine (Xeloda) compared with trastuzumab/ capecitabine and placebo in those who had prior treatment with trastuzumab, pertuzumab (Perjeta), and ado-trastuzumab emtansine (T-DM1; Kadcyla).
The ongoing phase 2 BRIDGET trial (NCT05323955) of patients with advanced HER2-positive breast cancer with isolated intracranial recurrence is evaluating stereotactic radiosurgery with or without surgery followed by enrollment onto study, where they will receive standard trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib.